PW Medtech Group Co. Ltd.'s subsidiary, Sichuan Rekind Medtec., Inc., also known as Sichuan Ruijian Medical Technology Co. Ltd., has disclosed its financial performance for the first quarter of 2025. The company, which specializes in the R&D, manufacturing, and sales of blood purification medical devices and related products in China, presented its quarterly auditors' review report and financial statements on the National Equities Exchange and Quotation System. These results, prepared in line with China Accounting Standards for Business Enterprises, highlight the company's continued focus on its core medical device operations. The financial outcomes for Sichuan Ruijian Medical will later be incorporated into the broader accounts of PW Medtech Group, following necessary adjustments according to Hong Kong Financial Reporting Standards. Shareholders and investors are advised to consider these reviewed results carefully when engaging with the company's securities.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.